Hans Verbaan (Former)
1 – 39 of 39
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine
(
- Contribution to journal › Article
- 2018
-
Mark
Increased hope following successful treatment for hepatitis C infection
(
- Contribution to journal › Article
- 2017
-
Mark
Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis
(
- Contribution to journal › Article
-
Mark
Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis
(
- Contribution to journal › Article
- 2016
-
Mark
Akut njursvikt är en vanlig komplikation vid levercirros : Handlägg proaktivt för att förhindra ytterligare försämrad njurfunktion
(
- Contribution to journal › Article
- 2015
-
Mark
Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation
(
- Contribution to journal › Article
-
Mark
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
(
- Contribution to journal › Article
-
Mark
Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis - a long-term follow-up study in 634 Swedish patients
(
- Contribution to journal › Article
- 2013
-
Mark
A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
(
- Contribution to journal › Article
- 2012
-
Mark
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
(
- Contribution to journal › Article
-
Mark
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study
(
- Contribution to journal › Article
- 2011
-
Mark
IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection
(
- Contribution to journal › Article
-
Mark
The clinical importance in differentiating portal from mesenteric venous thrombosis.
(
- Contribution to journal › Article
- 2010
-
Mark
Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study
(
- Contribution to journal › Article
-
Mark
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
(
- Contribution to journal › Article
-
Mark
Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis.
(
- Contribution to journal › Article
-
Mark
Il28B Genetic Variation And Treatment Response In Patients With Hcv Genotype 3 Infection
2010) 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 52(4). p.898-898(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Health-related quality of life in patients with different stages of liver disease induced by hepatitis C
(
- Contribution to journal › Article
-
Mark
RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B
2009) 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver In Journal of Hepatology 50(Suppl 1). p.232-232(
- Contribution to journal › Published meeting abstract
-
Mark
High levels of serum antibodies to cell surface proteins of Helicobacter pullorum and Helicobacter pylori in hepatitis C virus-infected patients.
(
- Contribution to journal › Article
-
Mark
Low-To-Moderate Alcohol Consumption has no Impact on Antiviral Response to Combination Therapy In Hcv Patients with Genotype 2 or 3
2009) 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 50(4). p.819-819(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
(
- Contribution to journal › Article
-
Mark
IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS
2008) 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 48(4). p.1875-1875(
- Contribution to journal › Published meeting abstract
-
Mark
Prevalence of hepatitis C in Swedish diabetics is low and comparable to that in health care workers.
(
- Contribution to journal › Article
-
Mark
Prospective study of nosocomial transmission of hepatitis C in a Swedish gastroenterology unit .
(
- Contribution to journal › Article
-
Mark
Is sustained virological response to HCV treatment associated with a clinical important improvement in vitality?
2008) 43rd Annual Meeting of the European Association for the Study of the Liver In Journal of Hepatology 48(Suppl. 2). p.272-272(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection
(
- Contribution to journal › Article
-
Mark
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study
(
- Contribution to journal › Article
- 2002
-
Mark
High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.
(
- Contribution to journal › Article
- 2001
-
Mark
Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
(
- Contribution to journal › Article
-
Mark
GB virus C/hepatitis G virus infection in patients investigated for chronic liver disease and in the general population in southern Sweden
(
- Contribution to journal › Article
- 2000
-
Mark
Hepatocellular carcinoma in Sweden: its association with viral hepatitis, especially with hepatitis C viral genotypes
(
- Contribution to journal › Article
-
Mark
Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population
(
- Contribution to journal › Article
- 1999
-
Mark
Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjogren's syndrome and hepatitis C in Swedish patients
(
- Contribution to journal › Article
- 1998
-
Mark
Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence
(
- Contribution to journal › Article
-
Mark
Long-term outcome of chronic hepatitis C infection in a low-prevalence area
(
- Contribution to journal › Article
- 1997
-
Mark
Chronic hepatitis C infection. With special reference to prevalence, aggravating factors and longterm outcome
1997)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Serine protease inhibitors in patients with chronic viral hepatitis
(
- Contribution to journal › Article
- 1992
-
Mark
Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10-year period
(
- Contribution to journal › Article